Edgestream Partners, L.P. Neurocrine Biosciences Inc Transaction History
Edgestream Partners, L.P.
- $2.29 Billion
- Q4 2024
A detailed history of Edgestream Partners, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 12,574 shares of NBIX stock, worth $1.47 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
12,574
Previous 5,266
138.78%
Holding current value
$1.47 Million
Previous $606,000
183.17%
% of portfolio
0.07%
Previous 0.03%
Shares
15 transactions
Others Institutions Holding NBIX
# of Institutions
636Shares Held
94.2MCall Options Held
634KPut Options Held
603K-
Black Rock Inc. New York, NY14.2MShares$1.66 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.18 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$602 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$301 Million0.47% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$219 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...